VAERS Explorer
Back to explore

Report #2851861

Received Jul 30, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
—
Recovered
Unknown
Vaccinated
Jul 16, 2025
Onset
Jul 16, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2UNK—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Second dose was administered 46 days after the first Shingrix vaccine; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of drug dose administration interval too short in a patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 16-JUL-2025, the patient received the 2nd dose of Shingrix (unknown deltoid). On 16-JUL-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Second dose was administered 46 days after the first Shingrix vaccine). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 21-JUL-2025 The pharmacist reported that a patient was administered second dose of vaccine 46 days after the first dose of Shingrix vaccine which led to shortening of vaccination schedule.

Other medications

SHINGRIX